Chongqing International Institute for Immunology is located in Chongqing International Biological City, with a total construction area of 40,000 square meters. It is a new system and new business research institute established by the Chongqing Municipal Government. Aiming at the international frontiers and hot spots, the Institute gathers high-end innovative resources such as intelligence, technology, results, and capital, and is committed to building a high-level research platform that integrates original research on theory and technology, application research on innovative technologies, and research and development of innovative immune biological products, including advanced Immune cell and molecule decoding platform, "2+4+X" R&D innovation platform ("2" refers to vaccines and antibodies; "4" refers to peptide drugs, immune cell therapy, immunodiagnosis, ARO services; "X" refers to immune big data And artificial intelligence center, pilot production center, laboratory animal center, cell decoding center, biological sample library, large-scale equipment center, etc.). The Institute will advance the international first phase III clinical trials and product listings of the FDA and CFDA mock antigen vaccines in stages, as well as the entry of 12 "new drug creation" national science and technology projects under development into clinical trials.